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Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes
containing, for example, integrins, growth factor receptors and matrix metalloproteases, and modify their
functions in cell adhesion, migration and transmembrane signaling. CD151 is part of the tetraspanin family and it forms
tight complexes with β1 and β4 integrins, both of which have been shown to be required for tumorigenesis and/or
metastasis in transgenic mouse models of breast cancer. High levels of the tetraspanin CD151 have been linked to poor
patient outcome in several human cancers including breast cancer. In addition, CD151 has been implicated as a
promoter of tumor angiogenesis and metastasis in various model systems.
Methods: Here we investigated the effect of Cd151 deletion on mammary tumorigenesis by crossing Cd151-deficient
mice with a spontaneously metastasising transgenic model of breast cancer induced by the polyoma middle T antigen
(PyMT) driven by the murine mammary tumor virus promoter (MMTV).
Results: Cd151 deletion did not affect the normal development and differentiation of the mammary gland. While
there was a trend towards delayed tumor onset in Cd151−/− PyMT mice compared to Cd151+/+ PyMT littermate
controls, this result was only approaching significance (Log-rank test P-value =0.0536). Interestingly, Cd151 deletion
resulted in significantly reduced numbers and size of primary tumors but did not appear to affect the number or
size of metastases in the MMTV/PyMT mice. Intriguingly, no differences in the expression of markers of cell
proliferation, apoptosis and blood vessel density was observed in the primary tumors.
Conclusion: The findings from this study provide additional evidence that CD151 acts to enhance tumor formation
initiated by a range of oncogenes and strongly support its relevance as a potential therapeutic target to delay breast
cancer progression.
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Breast cancer is the most commonly diagnosed cancer
among women and despite some major advances in diag-
nosis and treatment, it remains the second leading cause of
cancer death in women worldwide. Similarly to other can-
cers, some of the major challenges in the treatment of
breast cancer reside in the lack of response or development* Correspondence: severine.roselli@newcastle.edu.au
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unless otherwise stated.of resistance to existing therapies and the devastating
consequences of metastasis. Better prognostic markers as
well as new targeted treatments that could be used alone,
or most likely in combination with existing therapies are
needed to improve patient outcomes.
The tetraspanin CD151 is part of the tetraspanin family
of transmembrane proteins, which consists of 33 members
in humans. These proteins serve as scaffolds for multipro-
tein complexes (called TEMs or Tetraspanin-Enriched
Microdomains) where they associate with molecules
such as integrins, growth factor receptors and matrix
metalloproteases, modifying their functions in various
cellular processes. CD151 forms tight complexes with
the laminin binding integrins (α3β1, α6β1 and α6β4)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rin mediated cell adhesion and motility.
Interestingly, β1-integrin and β4-integrin- heterodimers
(reviewed in [2]) are both expressed by breast epithelial
cells (mostly as α3β1 and α6β4) and have been shown to
be required for tumorigenesis and metastasis in the
MMTV/PyMT and MMTV/Neu (rat homolog of ErbB2)
mouse models of breast cancer [3,4], respectively. CD151
expression itself has been associated with poor patient
outcome in several malignancies, including cancers of the
breast [5,6], prostate [7], lung [8], and kidney [9], whereas
it has also been found to correlate with improved survival
in endometrial cancer [10]. Notably in breast cancer,
elevated expression of CD151 correlates with lymph node
invasion and poor overall survival of patients with invasive
ductal carcinoma [5,6]. In accordance with its association
with poor prognostic in patients, CD151 has been impli-
cated as a promoter of tumor angiogenesis and/or metas-
tasis in vitro in human breast cancer cell lines and in
several in vivo model systems including xenografts [5,11],
matrigel plug and tumor implantation experiments [12],
as well as experimental metastasis models [13,14]. In
addition, a recent study showed that CD151 plays a role in
mammary cell proliferation, suggesting the involvement of
CD151 in tumor cell growth [15].
Altogether these data strongly indicate a role for CD151
in tumor growth and metastasis, suggesting that it could
be used as a target molecule for the design of new breast
cancer therapies. However, when we started this work, the
possible direct cause-effect relationship between CD151
expression and breast tumor onset/progression and me-
tastasis had never been tested. In order to address this
question, we studied the effect of Cd151 deletion on
de novo breast tumorigenesis and spontaneous metastasis
in the very well characterized MMTV/PyMT transgenic
breast cancer mouse model [16]. In this model, the poly-
oma middle T oncogene is expressed under the trans-
criptional control of the mouse mammary tumor virus
promoter. The mammary tumors that develop in MMTV/
PyMT female mice recapitulate the histological stages of
human breast cancer from premalignant lesions to inva-
sive carcinoma [17] and they also display activation of the
same signaling pathways that act downstream of the
ErbB2 oncogene and are often activated in breast cancer,
such as c-Src, PI3K and Ras [18].
It is interesting to note that a study addressing the
impact of Cd151 deletion in another mouse model of
breast cancer (the ErbB2 model) has recently been pub-
lished by Deng and colleagues [19]. The results from
both studies will be compared in the discussion.
Here we show that Cd151–null mice develop smaller and
fewer PyMT mammary tumors than their age matched con-
trols. Our results suggest that Cd151 deletion impairs tumor
initiation and/or tumor growth in the MMTV/PyMTmodel, while an apparent effect on tumor metastasis could
be attributable to larger tumor burden in Cd151+/+ mice.
Methods
Experimental animals
Animal maintenance was in accordance with the Animal
Care and Ethics Committee at the Australian BioResources
specific pathogen free (SPF) animal breeding facility (Moss
Vale, New South Wales). All animal monitoring and exper-
iments were approved by the Animal Care and Ethics
Committee at the University of Newcastle. In the tumori-
genesis experiments, we used the well-characterized FVB/
N (FVB) MMTV/PyMT mouse line (MT#634) carrying a
mouse mammary tumor virus promoter-driven polyoma
middle T transgene [16]. A pure FVB genetic background
is most commonly used for mouse tumorigenesis experi-
ments because of its permissiveness to spontaneous tumor
development. Cd151−/− mice are grossly healthy on the
C57Bl/6 (B6) background [20] but they develop a severe
kidney disease on a pure FVB background [21]. Hence
FVB Cd151−/− mice could not be used for the tumorigen-
esis experiments. Since F1 hybrid FVB x B6 Cd151−/− mice
were healthy and did not present any sign of kidney disease
onset (monitored for the appearance of proteinuria over a
12 months period, our unpublished data), we conducted
the experiments on this hybrid background. This allowed
us to keep all experimental animals on a mixed but yet
homogenous (50% B6 and 50% FVB) genetic background.
FVB Cd151+/− mice were produced by backcross for 10
generations from the original B6 Cd151−/− [20] and main-
tained as heterozygotes. Heterozygous B6 Cd151+/− fe-
males were crossed with FVB Cd151+/− males carrying the
MMTV/PyMT transgene (PyMT Cd151+/− males, see
Additional file 1: Figure S1 for breeding details) in order to
generate the experimental F1 animals. Genotyping was
performed as previously described [20]. Experimental and
control littermates were co-housed throughout the experi-
ments, in a temperature controlled facility with a 12-h
light: dark cycle.
Animal monitoring and tissue collection
Beginning at weaning (3 weeks of age), female mice were
palpated twice weekly for the onset of mammary tumors.
For each mouse, tumor palpation was performed in each
of the ten mammary glands, in a genotype-blinded fash-
ion. At 15–16 weeks of age, female mice were euthanased
by CO2 inhalation, and all the tumors were dissected and
weighed. For each experimental mouse, half of the biggest
tumor was fixed in 10% neutral buffered formalin (NBF)
for paraffin embedding, one quarter was snap frozen in
liquid nitrogen, and the last quarter was snap frozen
in OCT compound. At the time of dissection and after ex-
cision of the tumors, the lungs were exposed and inflated
via tracheal injection of 1 ml of 10% NBF in order to
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further fixed in 10% NBF for at least 24 hours before par-
affin embedding.Whole mount analysis
Whole mount analysis was performed by spreading
inguinal #4 mammary glands onto poly-lysine slides
followed by overnight fixation in 10% NBF, defatting in
acetone and overnight staining in carmine alum (0.2%
carmine and 0.5% aluminium sulphate) as previously
described [22]. The stained glands were then dehy-
drated in a graded ethanol series, incubated in xylene
for 1 hour and stored in methyl salicylate.Tumor histology and immunohistochemistry
Tumor histology/stage was assessed on the largest
tumor for each mouse using 5 μm paraffin sections
stained with hematoxylin and eosin. Immunohisto-
chemistry (IHC) was performed on 5 μm paraffin sections
using a peroxidase VECTASTAIN ABC elite kit and DAB
peroxidase substrate kit as per the manufacturer’s recom-
mendations (Vector Laboratories, Burlingame, CA). The
antibodies and dilutions used for IHC were rabbit
monoclonal anti-Ki67 at 1:200 (Neomarkers, Kalamazoo,Figure 1 Whole mount analysis of mammary gland
development in Cd151+/+ and Cd151 −/− mice. The morphology
of whole mount #4 mammary glands was analysed at different
stages in FVB Cd151+/+ and Cd151−/− mice. Mammary gland
development was assessed in virgin glands (V, top panel) and
appeared to occur normally in Cd151−/− animals as compared to
Cd151+/+ mice. Mammary gland differentiation during pregnancy
(day 17 of pregnancy, middle panel) and lactation (lactation day 2,
bottom panel) was also unchanged in Cd151 −/− mice.MI, USA) and polyclonal rabbit anti-cleaved caspase 3 at
1:800 (Cell Signaling Technology, Danvers, MA, USA).
Immunofluorescence labeling
Immunofluorescence labelings were performed on 5 μm fro-
zen sections as previously described [21]. Primary antibodies
and dilutions used for immunofluorescence labeling were
rabbit anti-CD151 (LAI-2) at 1:500 [21]; rat anti-CD31 (BD
Biosciences, Franklin Lakes, NJ, USA) at 1:200; rabbit anti-
α3 integrin (a kind gift from Dr. Fiona Watt, Wellcome
Trust Centre for Stem Cell Research, Cambridge, UK) at
1:1000; rat anti-β1 integrin (BD Biosciences) at 1:200; rat
anti-β4 integrin (BD Biosciences) at 1:200; rat anti- α6 integ-
rin (Chemicon, Temecula, CA, USA) at 1:200. The double
labeling where two rabbit primary antibodies were used
(CD151 and α3 integrin) was performed sequentially follow-
ing established methods as described previously [21].
Quantitation of tumor cell proliferation, apoptosis and
vascularization
The largest tumor for each mouse was used to quanti-
tate proliferation, apoptosis and vascularization in a
genotype-blinded manner. Tumor cell proliferation wasFigure 2 Localization of CD151 in the wild-type mouse mammary
gland. Dual immunofluorescent labeling and confocal analysis
using CD151 antibodies (green) and antibodies towards the
integrin chains β1 (A-C), β4 (D-F), α3 (G-I) and α6 (J-L) in red.
CD151 co-localizes with these 4 chains of integrins in the basal cell
layer of the mammary epithelium and the basolateral membrane of
luminal epithelial cells. Original magnification ×400.
Figure 3 Expression of CD151 in mammary tumors. Dual
immunofluorescent labeling and confocal analysis using CD151
antibodies (green) and antibodies towards β1-(A-F), or β4-integrin
(G-L) were performed on Cd151+/+ MMTV/PyMT mammary tumors
at the adenoma stage (A-C and G-I) and the carcinoma stage
(D-F and J-L) (stages as defined by Lin et al. [17]). At the early
adenoma stage (A-C and G-I), the tumor cells showed faint
CD151 expression overall that was more intense on the edge of
the tumor nodules, colocalizing with β1 and β4 integrins along
the basement membrane. At a more advanced tumor stage, the
labeling was more patchy with still some degree of colocalization
with integrins (D-F and J-L). Original magnification ×400.
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above) for the commonly used Ki67 nuclear marker. Ki67
stained slides were scanned in a digital format using the
Aperio™ digital pathology system (Aperio) and 200× mag-
nification snapshots of digital images were generated using
Imagescope. Quantitation of proliferation (expressed as
percent Ki67 positive nuclear area per total nuclear area)
was then performed on the 200× digital images using
ImmunoRatio, a publicly available web-based application
[23]. The extent of apoptosis in the tumors was quanti-
tated on Aperio images of cleaved-caspase 3 IHC
stained slides, using the positive pixel count algorithm
at 200× magnification (5 fixed size (300 μm × 300 μm)
images were used for each tumor section).
To estimate blood vessel density, CD31 immunofluores-
cence labeling was performed and Image J was used to
quantitate the proportion of CD31 positive area inside the
tumors. At least five fluorescent microscope pictures (100×
magnification) per tumor were used in the CD31 analysis.
Analysis of lung metastasis
All the lung lobes were dissected and processed for par-
affin embedding. Five microns paraffin sections were
stained with hematoxylin and eosin and slides were
scanned in a digital format using the Aperio™ digital
pathology system (Aperio). The lung area per section
was measured using Scanscope and the metastatic bur-
den (mm2 of metatastases/cm2 lung) was calculated for
each animal, using the data from 3 sections at least
100 μm apart, as previously described [24].
Statistical analysis
Statistical analysis was conducted using Prism 6 (Graphpad
software). Kaplan-Meier survival curves were analysed
with the log-rank test. Metastasis distribution was assessed
with a contingency table and Chi-square test. All the other
data sets were submitted to the Shapiro-Wilk normality
test and depending on the result of this test, parametric or
non-parametric comparison tests were performed. Specific
tests used for each data set are mentioned in the figure
legends. In all tests, P-values <0.05 were considered
significant.
Results
Deletion of Cd151 does not interfere with mammary
gland development and differentiation
Before investigating the effect of Cd151 deletion on
mammary tumorigenesis it was necessary to determine
whether mammary gland development and differenti-
ation was normal in Cd151 knock-out mice. For this
purpose, we performed whole mount analysis of #4
inguinal mammary glands in virgin, pregnant and lac-
tating FVB Cd151+/+ and Cd151−/− mice (Figure 1).
Ductal outgrowth and mammary gland differentiationappeared grossly normal in the Cd151−/− females at the
different stages of development investigated.
Expression pattern of CD151 in the normal mammary
gland and PyMT mammary tumors
Immunofluorescence labeling of 6-week old virgin mam-
mary glands and confocal microscopy revealed strong
expression of CD151 in the mammary ducts in a basolat-
eral pattern (Figure 2), reminiscent of the surrounding
basal layer of myoepithelial cells and in accordance
with what has been previously reported in humans [11].
Fainter CD151 labeling was also noticeable in the baso-
lateral membrane of ductal luminal cells (Figure 2A).
Moreover, CD151 labeling in the mammary ducts
colocalized to some extent with the α3-, α6-, β1- and
β4- chains of integrins, suggesting association of CD151
with the α3β1, α6β1 and α6β4 integrin heterodimers in
the mammary gland. Similarly to the situation in
the normal glands, CD151 appeared to be expressed
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the tumor nodules of the early stage PyMT tumors,
while the cancer cells in the nodules were only faintly
labeled (Figure 3). The CD151 labeling overlapped to
some extent with the β1- and β4- integrin immunola-
belings in the tumors suggesting as expected some de-
gree of colocalization.
Loss of Cd151 significantly decreases mammary tumor
multiplicity and growth
To avoid the kidney phenotype that has been described
in FVB Cd151−/− mice [21], we chose to investigate the
effects of Cd151 deletion on mammary tumorigenesis on
a F1 (FVB×B6) background (see explanations in Methods).
Consistent with previous reports showing increased PyMT
tumor latency on the B6 background [24,25], the onset
of mammary tumors was significantly delayed by about
20 days on the (FVBxB6) F1 background in comparison to
the pure FVB background (Additional file 2: Figure S2).
Investigation of mammary tumor onset by palpation
showed no statistically significant difference in tumorFigure 4 Effect of Cd151 deletion on MMTV/PyMT tumor onset and g
MMTV/PyMT Cd151+/+, Cd151+/− and Cd151−/− mice by bi-weekly palpatio
the median time to development of a palpable mammary tumor for each gro
groups or between the Cd151+/+ and the Cd151+/− groups were not stat
Tumor multiplicity (B), total tumor weight (C) and the weight of the bigg
The horizontal bars on the graphs represent the median for each parameter. T
The number of tumors (B, P= 0.0003), the total tumor weight per mouse (C, P
were significantly decreased in the Cd151−/− group compared to the Cd151+/+
with Cd151+/− groups or Cd151+/− with Cd151−/− respectively.latency between Cd151+/+ and Cd151−/− PyMT mice
(Figure 4A). There was however a trend towards increased
tumor latency in Cd151−/− (T50 = 67 days; n = 25) as com-
pared to Cd151+/+ (T50 = 61.5 days; n = 26) that was ap-
proaching significance (Log-rank test P-value =0.0536).
Interestingly, the median age to tumor onset in the hetero-
zygous Cd151+/− mice was in between the values reported
for Cd151+/+ and Cd151−/− PyMT mice (Cd151+/− T50 =
63, n = 21). However, the difference between the median
tumor latency of Cd151+/− versus Cd151+/+ mice was not
significant (Log-rank test P = 0.7533).
At 15 to 16 weeks of age (i.e. 6 to 7 weeks after initial
tumor palpation), the mice were euthanased and all the
tumors were collected and weighed for each mouse.
Interestingly both the total tumor weight (P = 0.0003)
and tumor multiplicity (P = 0.0008) per mouse were
significantly decreased in the Cd151−/− group as com-
pared to Cd151+/+ group (Figure 4B and 4C). Individ-
ual tumor weight (as shown with weight of the largest
tumor per mouse Figure 4D) was also clearly decreased
in Cd151−/− mice (P = 0.0023), suggesting an effect ofrowth. (A) The appearance of mammary tumors was monitored in
n and is represented on a Kaplan-Meier survival curve. T50 indicates
up of mice. The differences in T50 between Cd151
+/+ and Cd151−/−
istically significant (log rank test P = 0.0536 and P = 0.7533, respectively).
est tumor per mouse (D) were measured at the time of euthanasia.
he results were compared using the non-parametric Krustal-Wallis test.
= 0.0002) and the weight of the biggest tumor per mouse (D, P = 0.0014)
. mice. There were no significant differences when comparing Cd151+/+
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tion and growth/proliferation in vivo. Regardless of the
Cd151 genotype, at least part of the largest tumor of
each mouse had progressed to the carcinoma stage as
determined by H&E staining (illustrated in Figure 5).
Immunolabelings for Ki67, cleaved caspase-3 and CD31
were performed on representative primary tumor sam-
ples in order to compare the rates of cell proliferation,
apoptosis and tumor angiogenesis between both groups
of mice, respectively (Figure 6). These experiments did
not reveal any significant differences between Cd151+/+
and Cd151−/− tumors.Figure 5 Tumor histology of the MMTV/PyMT Cd151+/+, Cd151+/−
and Cd151−/− mice. At the end point, tumor histology (assessed by
H&E staining) was undistinguishable between the three groups of
mice. All mammary tumors presented features of the carcinoma
stage, independently of their Cd151 genotype.Effect of Cd151 deletion on development of lung
metastases
Since the mammary tumors of MMTV/PyMT mice pri-
marily metastasize to the lungs, we examined the lungs
of Cd151+/+ and Cd151−/− PyMT mice at the time of
dissection, which corresponds to 6 to 7 weeks after
tumor onset. The incidence of lung metastasis was simi-
lar in both groups with 22 out of 26 Cd151+/+ (85%) and
20 out of 24 Cd151−/− (83%) mice developing lung me-
tastases (Figure 7A). In addition, the median number of
lung metastases (Mann Whitney test P-value = 0.3554)
and the average size of individual metastasis per mouse
(Mann Whitney test P-value = 0.6757) were similar
between the two groups (Figure 7B and 7D, respect-
ively). The distribution of the number of metastases in
the Cd151+/+ group, was much more heterogeneous
(Figure 7B), with a large subset of the Cd151+/+ but not
Cd151−/− group of mice containing high numbers of
metastases (Chi-square P-value = 0.0329, Figure 7C).
On closer observation, it could be noted that the mice
with high number of metastases in the Cd151+/+ group
were also the mice with higher tumor burden (Figure 7E)
suggesting that tumour burden rather than Cd151 status
is the likely explanation. In conclusion, ablation of Cd151
per se did not appear to affect the number or size of me-
tastases in the MMTV/PyMT mice.
Discussion
In this study, we found that deletion of Cd151 signifi-
cantly impaired tumor development and progression in
the murine MMTV/PyMT breast tumorigenesis model.
These results are consistent with previous work investi-
gating CD151’s function in other breast tumor models,
suggesting that regardless of the tumor initiating onco-
gene, CD151 enhances tumor initiation and subsequent
progression. Whilst the increase in tumor latency in
Cd151−/− mice was only approaching significance, there
was significant decrease in the number of tumors per
mouse, suggesting that Cd151 deletion might impair
PyMT tumor initiation. This could be determined in
future experiments by assessing the early stages of
PyMT tumorigenesis (from the age of weaning) and
whether the extent of hyperplasia is different between
genotypes before a palpable tumor can be detected.
The decreased number of detectable tumors could also
reflect a pronounced defect in tumor growth. Indeed,
the size of the mammary tumors was also reduced in
Cd151−/− mice, as shown by the total tumor burden
per mouse (expressed as total tumor weight per
mouse), as well as the individual tumor weight (repre-
sented as the weight of the largest tumor for each
mouse). Intriguingly however we did not find a difference
in tumor vascularisation or tumor cell proliferation and
apoptosis that could explain the decreased tumor size in
Figure 6 Tumor cell proliferation, apoptosis and blood vessel density in Cd151+/+ and Cd151−/− mammary tumors. These parameters
were assessed by IHC for the cell proliferation marker Ki67 (A, P =0.1533), the apoptosis marker cleaved-caspase 3 (B, P =0.3476), and by
immunofluorescence for the endothelial cell specific antigen CD31 (C, P = 0.3035), respectively. Means ± SEM are represented and parametric
t-test was used to compare the data. Representative photos of the immunolabelings are also shown. Original magnification: ×200 for Ki67
and Cleaved-caspase 3 and ×100 for CD31.
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tumor proliferation and apoptosis reinforces the hypoth-
esis stated above that Cd151 deletion may act predomin-
antly by delaying PyMT tumor initiation, as suggested by
the trend towards delayed tumor onset and the decreased
number of tumors per mouse.
In recent years, Sadej and colleagues have reported a
decrease in tumor growth associated with CD151 knock-
down in a subcutaneous xenograft model [5]. Similar to
our result, CD151 knock-down did not have an effect on
overall vessel density in the xenografts. Interestingly how-
ever the authors of that study described a pronounced
decrease in the dense angiogenic network typically ob-
served at the subcutaneous border of this type of tumors.
We were not able to similarly assess the tumor border in
our model system due to the nature of the de novo
MMTV/PyMT tumors and because rich vascular networks
do not develop at the periphery of tumors in this model.
Tumor progression in the MMTV/PyMT model has
been very well characterized; it follows several well-
defined stages from hyperplasia to non-invasive aden-
oma and finally invasive carcinoma [17]. Loss of the
myoepithelial cell layer surrounding the hyperplastic
luminal epithelial structures is an important step in theprogression to invasive carcinoma in these tumors
[26,17]. Moreover, mammary myoepithelial cells have
been referred to as ‘natural tumor suppressors’ because
of their capacity to block tumor cell growth and inva-
sion [27,28]. Because CD151 is primarily expressed in the
mammary myoepithelial cells and the PyMT tumors arise
from luminal epithelial cells in the mammary gland where
CD151 has reduced expression, it is tempting to speculate
that Cd151 deletion could affect tumor development
indirectly through the microenvironment, by modify-
ing the phenotype of the myoepithelial cells. However
CD151 is also expressed, to a lesser extent, at the baso-
lateral membrane of the luminal epithelium. It would
be interesting to evaluate separately the specific effect
of Cd151 deletion in the stroma (tumor vasculature,
immune cells, myoepithelial cells) and the luminal
epithelium/tumor cells respectively, using a condi-
tional knock-out model. In addition, one could study
the tumor cell autonomous versus microenvironment
effect by performing orthotopic tumor grafts.
A recent study [19] investigated the impact of Cd151
deletion on tumor onset, growth and metastasis of
another well characterized mouse mammary tumor
model, the MMTV/Neu model (overexpressing multiple
Figure 7 Impact of Cd151 deletion on lung metastases. The incidence of lung metastasis (A), the median number of lung metastases (per cm2)
per mouse (B, P = 0.3554), and the average metastasis size per mouse (mm2) (D, P = 0.6757) were not different between Cd151+/+ (n = 26) and Cd151
−/− (n = 24) mice. Non-parametric Mann–Whitney test was used to compare the data in B and D and the horizontal bars indicate the median values.
The distribution of the number of metastases per mouse was much more heterogenous in the Cd151+/+ group (C): A significantly larger proportion of
Cd151+/+ (8/26) than Cd151−/− (1/24) mice had 10 or more metastatic foci per cm2 of lung (Chi square P value = 0.0329). (E) Correlation between the
number of metastases and the total tumor weight per mouse was assessed using the non parametric Spearman correlation test. The number of
metastases did not correlate with tumor burden in the Cd151−/− group (r = 0.117, P = 0.5861). There was however a strong correlation between number of
metastases and tumor weight in the Cd151+/+ group (r = 0.8046, P< 0.0001), which contains mice with larger tumor burden than the Cd151−/− group.
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their study, Deng and colleagues observed a significant
delay in tumor onset as well as a decreased number of
metastases per animal in the Cd151−/− and Cd151+/−
groups compared with Cd151+/+ and they also suggest
that the effects of CD151 in the MMTV/Neu model are
largely mediated through α6β4 integrin. Together our
data shows that Cd151 deletion significantly impairstumor occurrence and growth. On assessment of lung
metastasis, we obtained different results from Deng and
colleagues. The median incidence, number and size of
lung metastases did not vary with the Cd151 genotype
in our study, and the higher metastatic burden in a pro-
portion of wild-type mice was associated with increased
primary tumors. These results suggest that ablation of
Cd151 does not directly affect metastasis in the PyMT
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models will be required to elucidate the contradictory
effects on metastasis in the MMTV/Neu and MMTV/
PyMT models.
In addition, two other studies have assessed the role of
CD151 on de novo tumorigenesis in mouse cancer models
other than breast. Firstly, similarly to our results in the
PyMT breast cancer model, Takeda and colleagues have
demonstrated that CD151 promotes tumor incidence and
multiplicity in a skin carcinogenesis model [14]. Secondly,
recent work in our laboratory has shown that deletion of
Cd151 reduces spontaneous metastasis of prostate tumors
in the TRAMP model [29]. Altogether, the literature and
the data we report here identify CD151 as an enhancer of
de novo tumorigenesis and/or spontaneous metastasis
across a broad range of cancer types.
Interestingly, the functional role of CD151 in tumori-
genesis and metastasis has been mainly linked to its
association with the laminin receptors in the literature.
These adhesion receptors include mostly α3β1, α6β1
and α6β4 integrins in the mammary epithelium. Lam-
inin binding integrins have a well-documented role in
malignant cell processes regulating crucial functions
such as cell proliferation and invasion. β1-integrins
represent the most predominantly expressed integrins
in the mammary epithelium and their direct involve-
ment in mammary tumorigenesis has been extensively
demonstrated using mouse models of breast cancer.
For example, it has been shown that β1-integrin is
absolutely required for PyMT mammary tumor initi-
ation and progression [4,30]. Similarly, several studies
have demonstrated that ablation of crucial signaling
molecules downstream of β1-integrin such as focal ad-
hesion kinase (FAK) also dramatically decreased cancer
cell proliferation [31-33]. In contrast to the total block in
PyMT induced tumorigenesis, mammary epithelial dele-
tion of β1 integrin in an MMTV/Neu (activated ErbB2)
mouse model did not totally prevent tumor development.
Although it significantly delayed tumor onset, all of the
mice developed tumors that were histologically identical
to control mice [34]. The major effect of β1 deletion in the
context of activated ErbB2 mammary tumorigenesis was
the decrease in incidence of lung metastasis as well as
decreased metastatic burden. There is to our knowledge
no published report on the role of β4-integrin in the
MMTV/PyMT model but it has been shown however that
β4-integrin collaborates with ErbB2 to promote mammary
tumorigenesis [3,16] in the MMTV/Neu mouse model.
Conclusions
In summary, the results of this study show that CD151
enhances mammary tumor initiation and progression in
the MMTV/PyMT mouse model but no direct effect on
metastasis was demonstrated. The effects of Cd151deletion in the MMTV/PyMT model are likely to be me-
diated by a combination of both β1- and β4-integrins but
this remains to be tested. In conclusion, our findings
strongly support the relevance of CD151 as a potential
therapeutic target to delay breast cancer progression.
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Additional file 2: Figure S2. Effect of the genetic background on
MMTV/PyMT tumor onset. The appearance of mammary tumors in
wild-type pure FVB or F1 FVB:B6 mice was monitored by bi-weekly
palpation and is represented on a Kaplan-Meier survival curve. T50
indicates the median time to development of a palpable mammary
tumor for each group of mice. The difference in T50 between FVB (42 d)
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